Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R-/- mice

被引:18
作者
Rafferty, Eamon P. [1 ]
Wylie, Alastair R. [2 ]
Hand, Katharine H. [1 ]
Elliott, Chris E. [1 ]
Grieve, David J. [3 ]
Green, Brian D. [1 ]
机构
[1] Queens Univ Belfast, Sch Biol Sci, Belfast BT9 5AG, Antrim, North Ireland
[2] Agri Food & Biosci Inst, Belfast 3T9 5PX, Antrim, North Ireland
[3] Queens Univ Belfast, Royal Victoria Hosp, Sch Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland
关键词
bile acids; endocrine; GLP-1; glucose; gut hormones; incretin; intestine; secretion; GLUCAGON-LIKE PEPTIDE-1; HIGH-FAT DIET; DIABETIC OB/OB MICE; NUCLEAR RECEPTOR; GLYCEMIC CONTROL; INCRETIN; EXENDIN(9-39)AMIDE; THERAPY; AGONIST; CELLS;
D O I
10.1515/BC.2011.050
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Physiological secretion of bile acids has previously been linked to the regulation of blood glucose. GLP-1 is an intestinal peptide hormone with important glucose-lowering actions, such as stimulation of insulin secretion and inhibition of glucagon secretion. In this investigation, we assessed the ability of several bile acid compounds to secrete GLP-1 in vitro in STC-1 cells. Bile acids stimulated GLP-1 secretion from 3.3- to 6.2-fold but some were associated with cytolytic effects. Glycocholic and taurocholic acids were selected for in vivo studies in normal and GLP-1R(-/-) mice. Oral glucose tolerance tests revealed that glycocholic acid did not affect glucose excursions. However, taurocholic acid reduced glucose excursions by 40% in normal mice and by 27% in GLP-1R(-/-) mice, and plasma GLP-1 concentrations were significantly elevated 30 min post-gavage. Additional studies used incretin receptor antagonists to probe involvement of GLP-1 and GIP in taurocholic acid-induced glucose lowering. The findings suggest that bile acids partially aid glucose regulation by physiologically enhancing nutrient-induced GLP-1 secretion. However, GLP-1 secretion appears to be only part of the glucose-lowering mechanism and our studies indicate that the other major incretin GIP is not involved.
引用
收藏
页码:539 / 546
页数:8
相关论文
共 45 条
[1]   Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance [J].
Ayala, Julio E. ;
Bracy, Deanna P. ;
James, Freyja D. ;
Burmeister, Melissa A. ;
Wasserman, David H. ;
Drucker, Daniel J. .
ENDOCRINOLOGY, 2010, 151 (10) :4678-4687
[2]   Biology of incretins: GLP-1 and GIP [J].
Baggio, Laurie L. ;
Drucker, Daniel J. .
GASTROENTEROLOGY, 2007, 132 (06) :2131-2157
[3]  
Burington R.S., 1973, Handbook of mathematical tables and formulas, V5th
[4]   INCRETIN CONCEPT TODAY [J].
CREUTZFELDT, W .
DIABETOLOGIA, 1979, 16 (02) :75-85
[5]  
DEBARROS SG, 1982, GASTROENTEROLOGY, V82, P647
[6]   Recent Advances in Antidiabetic Drug Therapies Targeting the Enteroinsular Axis [J].
Flatt, P. R. ;
Bailey, C. J. ;
Green, B. D. .
CURRENT DRUG METABOLISM, 2009, 10 (02) :125-137
[7]   Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes [J].
Flatt, Peter R. ;
Bailey, Clifford J. ;
Green, Brian D. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :3648-3660
[8]   Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy [J].
Fonseca, Vivian A. ;
Rosenstock, Julo ;
Wang, Antonia C. ;
Truitt, Kennetit E. ;
Jones, Michael R. .
DIABETES CARE, 2008, 31 (08) :1479-1484
[9]   CHOLESTYRAMINE THERAPY FOR DYSLIPIDEMIA IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A SHORT-TERM, DOUBLE-BLIND, CROSSOVER TRIAL [J].
GARG, A ;
GRUNDY, SM .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :416-422
[10]   Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice:: evidence that GIP is the major physiological incretin [J].
Gault, VA ;
O'Harte, FPM ;
Harriott, P ;
Mooney, MH ;
Green, BD ;
Flatt, PR .
DIABETOLOGIA, 2003, 46 (02) :222-230